61
CanSino Biologics Inc.
6185.HK · HKSE
$35.18 +0.46% (+$0.16)
1M +32.35%
Market Cap ¥10.6B
P/E Ratio 259.70x
Div. Yield -
ROE 0.82%
Analiză
Un raport AI despre afacere, finanțe, evaluare, sentiment, știri și riscuri - scris în câteva minute.
Piotroski F-Score Moderate
6/9Valuation
13 /100
Expensive P/S 8.60x
P/E 259.70x
P/B 2.12x
Growth
16 /100
Declining Book val. growth 9.78%
Rev. growth 0.03%
FCF growth N/A
Profitability
25 /100
Weak Op. margin 4.62%
Gross margin 71.69%
FCF margin 10.47%
Quality
4 /100
Poor ROA 0.59%
ROIC 0.82%
Asset turnover 0.18x
Debt
80 /100
Low Int. coverage -2.08x
Debt/Equity 0.20x
Net debt/EBITDA -5.05x
Stability
21 /100
Unstable EPS volatility 90.50%
Beta 1.13x
Profitable years 1
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre 6185.HK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Xue Feng Yu
Employees
1,175
Headquarters
Tianjin
Evenimente viitoare
28 OCT.
Earnings
Upcoming earnings report
30 MAR.
Earnings
Upcoming earnings report